- Targeted Therapy
- Radiation Therapy
- Biological Therapy
Melanoma Treatment Market size was valued at USD 3. 24 billion in 2021 and is expected to reach USD 7.19 billion by 2028, with a CAGR of 15.92% during the forecast period 2022-2028. Melanoma is the more serious type of cancer which develops in cells of skin called melanocytes that produce melanin. Melanoma not only affects skin but it also affects eyes and rarely, affects internal organs such as the intestine. The exact cause of melanoma is not clearly known, but the exposure of skin to UV radiation or tanning lumps and beds increases risk of developing melanoma. Upsurge in the global melanoma prevalence rates and pipeline drugs for the treatment of melanoma projected to boost the global melanoma treatment market at significant rates over the forecast period. According to World Health Organization (WHO), there is continuous increase in global prevalence of melanoma worldwide and estimated to be 132,000 melanoma skin cancers occurs every year. Companies in marketplace are focused on development of the new drug treatments and identification of different noel targets for the treatment of melanoma. For instance, binimetinib is being developed by Array BioPharma under phase 3 clinical trials for various types of cancers including melanoma. Furthermore, companies also focus on collaborations and acquisitions to develop the new drug treatments and expanding their portfolio in melanoma treatment market. Key Developments: In September 2017 Merck Sharp & Dohme launched its blockbuster drug Keytruda in India for the treatment of unresectable or metastatic melanoma.
Fastest Growing Market
Melanoma treatment market is primarily driven by the increase in number of people suffering from melanoma coupled with the advancements and new drug approvals such as keytruda, vemurafenib, dabrafenib and nivolumab for the treatment of melanoma. In addition, growing number of drug developments, current pipeline drugs and their expected approvals during the forecast period projected to boost the melanoma treatment market over the forecast period. Furthermore, increase in government support and R&D activities to fight against cancer coupled with various initiatives by government and non-government organizations expected to bolster the market growth over the forecast period.
The melanoma treatment market is projected to expand at a CAGR of 15.92% CAGR during the forecast period
Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Novartis AG, Genetech Inc, AstraZeneca plc.
North America is the fastest-growing region for the melanoma treatment market